Compare HEQ & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HEQ | SERA |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.9M | 130.5M |
| IPO Year | N/A | 2021 |
| Metric | HEQ | SERA |
|---|---|---|
| Price | $10.78 | $3.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 43.1K | ★ 56.9K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 9.78% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $95,000.00 |
| Revenue This Year | N/A | $25.84 |
| Revenue Next Year | N/A | $347.37 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.06 |
| 52 Week Low | $9.08 | $1.37 |
| 52 Week High | $11.84 | $8.73 |
| Indicator | HEQ | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 60.36 |
| Support Level | $10.70 | $3.38 |
| Resistance Level | $10.82 | $3.66 |
| Average True Range (ATR) | 0.10 | 0.23 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 25.01 | 85.20 |
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.